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DNA flow cytometry of breast cancer fine needle aspirates
Sir - There are a number of points which I believe should be
raised with regard to the article by Mullen and Miller (1989)
on DNA flow cytometry of breast cancer fine needle
aspirates. First, I would point out that the authors have
omitted to reference previous contributions on the same topic
(Spyratos et al., 1987; Remvikos et al., 1988a, Briffod et al.,
1989). Second, as a cytometrist, I believe that data file histo-
grams should be presented (rather than redrawn ones) as
these usually contain extensive information on the quality of
the preparations (baseline, noise, skewed peaks, aggregates).
Third, the method of calculation of S-phase values should
always be stated.
The most important weakness of the article is the
definition of the variations on the histograms. For instance, a
modification of more than 5% in DNA index is considered
significant, where the standard deviation inherent in the
method of calculation (internal standard) is of 4%. From a
statistical point of view, a threshold of at least twice the
standard deviation should be used, i.e. 8%. Incidentally, the
committee on nomenclature of flow cytometry published its
recommendations in 1984 (Hiddeman et al., 1984), stipulating
that animal cells should definitely not be used as calibration
standards. To my knowledge, these recommendations have
been recognised by the Society of Analytical Cytology and
are followed by most cytometrists. As for the modifications
of cell populations, this is a very delicate point that should
be treated with much caution. A variation in the proportion
of the diploid cells could first of all be due to the presence of
a variable contingent of normal cells (lymphoid infiltrate for
example). Therefore, a precise score of the normal cells must
be established on control smears before a threshold of 10%
for a substantial difference between duplicate analyses can be
validated. Breast cancers are heterogeneous. This has been
shown by Auer et al. (1980), but also by our comparison of
FCM and cytogenetics for the same tumour (Remvikos et al.,
1988b), with sometimes a paradiploid and an aneuploid clone
being simultaneously present. Variations in the proportions
of the different cell populations in repeated samplings are
therefore to be expected.
A final point I wish to make concerns the usefulness of
iterative FNA in the assessment of response to treatment. By
analogy with in vitro experiments, modifications in the cell
cycle distribution are primarily to be expected (for instance
accumulation of cells in S or G2M). This was shown in the
pioneering work of Vindelov et al. (1982) and has been
confirmed for breast cancers (Spyratos et al., 1988; Remvikos
et al., 1988c).
DNA flow cytometry (FCM) is a promising method in
clinical oncology, in particular because of the possibility of
measuring DNA index and S-phase fractions (Kalionemi et
al., 1988). It was recently shown that DNA-ploidy and S-
phase fraction are significantly related to response to
cytotoxic chemotherapy (Briffod et al., 1989; Remvikos et al.,
1989). I believe that the article by Mullen and Miller can
only bring unjustified confusion to the minds of clinicians
who may be interested in FCM.
Yours etc.,
Y. Remvikos
Laboratory of Physiopathology,
Institut Curie,
26 rue d'Ulm,
75231 Paris, France.
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Response to the letter from Dr Remvikos
Sir - The letter from Dr Remvikos makes a number of
criticisms of our paper (Mullen & Miller, 1989) which we feel
are worth defending. With regard to the originality of the
article and the possible omission of other work (Spyratos et
al., 1987; Remvikos et al., 1988; Briffod et al., 1989), we feel
our work is indeed original. Both Spyratos and Remvikos,
while commenting on the clinical importance of sequential
FNAs for flow cytometric DNA analysis, do not provide any
data pertaining to reproducibility and variability of such
serial FNAs, although both studies, like our own, do provide
data comparing FNAs with surgically excised biopsies. The
third study (Briffod et al., 1989) was not in print when our
manuscript was accepted for publication, hence its exclusion
(along with Remvikos et al., 1989).344 LETTER TO THE EDITOR
In response to the comments relating to the way in which
we presented the DNA histogram data, we felt that diagram-
matic representations were the clearest way of illustrating the
similarities/differences exhibited. Had the article been pub-
lished in a more cytometrically orientated journal, we may
well have used the raw histograms. Debris was not a problem
since most samples yielded good quality histograms. S-phase
values were calculated using the para-1 software supplied by
Coulter for use with the EPICS-C.
Defining the degree of abnormality for the S-phase fraction
is, as Dr Remvikos states, a controversial issue - indeed we
spent considerable time choosing such an arbitary value.
However, providing this value is kept constant for all
analysis, results should remain valid. Chicken red blood cells
(CRBC) were used as an internal standard in this study since,
using a single batch preparation, they gave a reproducible
estimation of the DI of the diploid peak (0.997 ± 0.039). The
DI of aneuploid populations was calculated from the diploid
peak channel and not the CRBC channel. Despite recent
recommendations (Hiddeman et al., 1984), other studies con-
tinue to use only CRBCs (Abandowitz et al., 1987; Askens-
ten et al., 1988; Dressler et al., 1988; Stal et al., 1989).
Concerning the modifications of cell populations which are
seen to occur, we have clearly stated in the text that changes
may be due to (a) the proportion of tumour to non-tumour
cells in the aspirate, and (b) heterogeneity. To 'score' FNAs
for the number of 'normal' cells before DNA analysis may be
a valid criticism although this clearly applies to all FCM
analysis, regardless of source material. We fully agree with
Dr Remvikos in that variations in the proportions of
different cell populations in repeated samples are to be
expected due to heterogeneity (Auer et al., 1980; Kallioniemi
et al., 1988); indeed that is why serial FNAs may be so
susceptible to intersample variation.
While Dr Remvikos regards variations observed in serial
breast tumour FNAs as being analogous to in vitro
experiments, it is important to remember that studies involv-
ing cell lines are concerned with single homogenous popula-
tions and are therefore intrinsicly less likely to show
significant variations. The heterogenous nature of breast
tumours can only increase the intersample variations.
We do not underestimate the potential of FNAs in yielding
important prognostic information about breast cancer. How-
ever, we would wish to emphasise the potential pitfalls of
interpreting such sequential aspirates. While it is true that
successful treatment may be associated with marked
differences in the DNA profile from breast cancer cells, our
data clearly show that similar changes may be observed
following either no treatment or clinical failure to treatment.
It would therefore be irresponsible to suggest that changes in
the DNA content of FNAs represent an accurate method of
assessing clinical response. However, with the advent of bet-
ter markers of cellular proliferation and regression, this tech-
nology may well become an invaluable tool.
Yours etc.,
P. Mullen & W.R. Miller
ICRF Medical Oncology Unit,
Western General Hospital,
Edinburgh EH4 2XU, UK.
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